NCT00456898View on ClinicalTrials.gov

Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2007

Study Completion Date

March 31, 2007

Conditions
Depressive Disorder, MajorDiabetic NeuropathiesFibromyalgiaVasomotor Symptoms
Interventions
DRUG

desvenlafaxine sustained release (DVS SR)

DRUG

Paroxetine

DRUG

Codeine

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00456898 - Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway | Biotech Hunter | Biotech Hunter